DUBLIN, Ireland – Shrugging off uncertainties stemming from a string of recent – and looming – patent expiries, Eli Lilly and Co. is investing €330 million (US$443 million) in a new biopharmaceutical production facility at its Dunderrow campus, which is located near Kinsale, in County Cork, Ireland.
Shares in struggling German drug developer Paion AG soared by more than 30 percent Tuesday on news that its partner, Lundbeck A/S, was handing it a financial lifeline by agreeing to pay €20.1 million (US$27 million) to acquire all outstanding rights to its Phase III stroke drug desmoteplase.
DUBLIN, Ireland – Shrugging off uncertainties stemming from a string of recent – and looming – patent expiries, Eli Lilly and Co. is investing €330 million (US$443 million) in a new biopharmaceutical production facility at its Dunderrow campus, which is located near Kinsale, in County Cork, Ireland.
A new era in life sciences research in Norway is beginning this year. Two new programs, the Program on Human Biobanks and Health Data (BIOBANK) and a program called Biotechnology for Innovation (BIOTEK2021), are issuing their first call for proposals, with a total of NOK215 million (US$37.8 million) on offer initially.
Shares in Amsterdam Molecular Therapeutics Holding NV (AMT) fell by almost 19 percent Friday on news that venture capital investor Forbion Capital Partners had tabled an offer that would secure the company's immediate financial future, while taking it private in a manner that could ultimately result in small shareholders being squeezed out.
Shares in Amsterdam Molecular Therapeutics Holding NV (AMT) fell by almost 19 percent Friday on news that venture capital investor Forbion Capital Partners had tabled an offer that would secure the company's immediate financial future, while taking it private in a manner that could ultimately result in small shareholders being squeezed out.
Proving there is healthy demand for its shares as well as its advanced 3-D orthopedic imaging systems, EOS Imaging (Paris) grossed e37.9 million ($49.4 million) in an IPO on the NYSE Euronext Exchange in Paris that was 3.8 times over-subscribed.
With regulatory filings for its prostate cancer therapy, Alpharadin (radium-223 chloride), expected in mid-2012, Algeta ASA is seeking up to NOK260 million (US$45.4 million) in a private placement to enable it to establish a commercial base in the U.S. in advance of a product launch and to continue research and development of its second line of alpha emitters, based on thorium-227.
Pharnext SAS has unveiled €8 million (US$10.5 million) in new funding, which will enable the network pharmacology company to take its second drug development program, in Alzheimer's disease, into the clinic this year.
